Mód.
I

Lección 1. Epidemiología

Dra. Irene Moreno Torres

Título
Experto en Esclerosis Múltiple

Ayuda

PDF

 

conclusión

BIBLIOGRAFÍA

caso clínico

lecturas

links

Referencias bibliográficas

  1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;6736(18):1-15. [Pubmed]
  2. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169-80. [Pubmed]
  3. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520-32. [Pubmed]
  4. Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621-5. [Pubmed]
  5. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature. 1995 Sep;377(6545):150-1. [Pubmed]
  6. Multiple Sclerosis International Federation (MSIF). Atlas of MS 2013: Mapping Multiple Sclerosis Around the World. MSIF; 2013. Disponible en: [Enlace]
  7. Rivera VM. Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr Neurol Neurosci Rep. 2017;17(8)-57. [Pubmed]
  8. Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M; Platform TEMS. New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany. Mult Scler J. 2017;23(2s):78-90. [Pubmed]
  9. Caniglia-Tenaglia M, Guttmann S, Monaldini C, Manzaroli D, Volpini M, Stumpo M, et al. Multiple sclerosis in the Republic of San Marino, Italian peninsula: an incidence and prevalence study from a high-risk area. Neurol Sci. 2018;39(7):1231-6. [Pubmed]
  10. Kapica-Topczewska K, Brola W, Fudala M, Tarasiuk J, Chorazy M, Snarska K, et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord. 2018;21:51-5. [Pubmed]
  11. Battaglia MA, Bezzini D. Estimated prevalence of multiple sclerosis in Italy in 2015. Neurol Sci. 2017;38(3):473-9. [Pubmed]
  12. Poser CM. The dissemination of multiple sclerosis: ¿a Viking saga? A historical essay. Ann Neurol. 1994 Dec;36 Suppl 2:S231-43. [Pubmed]
  13. Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 2015 Oct;47(10):1107-13. [Pubmed]
  14. Grønlie SA, Myrvoll E, Hansen G, Grønning M, Mellgren SI. Multiple sclerosis in North Norway, and first appearance in an indigenous population. J Neurol. 2000;247(2):129-33. [Pubmed]
  15. Marrosu MG, Murru MR, Costa G, Cucca F, Sotgiu S, Rosati G, et al. Multiple Sclerosis in Sardinia Is Associated in Linkage Disequilibrium with HLA-DR3 and DR4 alleles. Am J Hum Genet. 1997;61:454-7. [Pubmed]
  16. Dean G, Yeo TW, Goris A, Taylor CJ, Goodman RS, Elian M, et al. HLA-DRB1 and multiple sclerosis in Malta. Neurology. 2008;70(2):101-5. [Pubmed]
  17. Ramagopalan SV, Morris AP, Dyment DA, Herrera BM, DeLuca GC, Lincoln MR, et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet. 2007;3(9):1607-13. [Pubmed]
  18. Baranzini SE, Oksenberg JR. The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. Trends Genet. 2017;33(12):960-70. [Pubmed]
  19. International Multiple Sclerosis Genetics Consortium; International Multiple Sclerosis Genetics Consortium. Low frequency and rare coding variation contributes to multiple sclerosis risk. Cell. 2018 (18) 31261-3. [Pubmed]
  20. McLeod JG, Hammond SR, Kurtzke JF. Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration. J Neurol. 2011;258(6):1140-9. [Pubmed]
  21. Belbasis L, Bellou V, Evangelou E, Ioannidis JPA, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015;14(3):263-73. [Pubmed]
  22. Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, Giovannoni G, et al. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler J. 2013;19(2):162-6. [Pubmed]
  23. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol. 2016;36(1):103-14. [Pubmed]
  24. Kvistad S, Myhr K-M, Holmøy T, Bakke S, Beiske AG, Bjerve KS, et al. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Mult Scler J. 2014;20(14):1833-40. [Pubmed]
  25. Castellazzi M, Tamborino C, Cani A, Negri E, Baldi E, Seraceni S, et al. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Mult Scler. 2010;16(7):883-7. [Pubmed]
  26. Van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GMGM. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult Scler J. 2016;22(3):279-91. [Pubmed]
  27. Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018;13(2):1-19. [Pubmed]
  28. Burnard S, Lechner-Scott J, Scott RJ. EBV and MS: ¿Major cause, minor contribution or red-herring? Mult Scler Relat Disord. 2017;16(February):24-30. [Pubmed]
  29. Sundqvist E, Bergström T, Daialhosein H, Nyström M, Sundström P, Hillert J, et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler. 2014;20(2):165-73. [Pubmed]
  30. Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, et al. Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Mult Scler. 2016 May;22(6):741-52. [Pubmed]
  31. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol. 2007;61(2):97-108. [Pubmed]
  32. Degelman ML, Herman KM. Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation. Mult Scler Relat Disord. 2017;17:207-16. [Pubmed]
  33. Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler J. 2012;18(9):1334-6. [Pubmed]
  34. Farez MF, Fiol MP, Gaitán MI, Quintana FJ, Correale J. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):26-31. [Pubmed]
  35. Farrokhi M, Dabirzadeh M, Fadaee E, Beni AA, Saadatpour Z, Rezaei A, et al. Polymorphism in Leptin and Leptin Receptor Genes May Modify Leptin Levels and Represent Risk Factors for Multiple Sclerosis. Immunol Invest. 2016;45(4):328-35. [Pubmed]
  36. Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De Rosa V, et al. Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. Clin Immunol. 2017;183:249-53. [Pubmed]
  37. Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84(4):427-32. [Pubmed]
  38. Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis. An update. Mult Scler Relat Disord. 2017;14:35-45. [Pubmed]
  39. Zheng C, He L, Liu L, Zhu J, Jin T. The efficacy of vitamin D in multiple sclerosis: a meta-analysis. Mult Scler Relat Disord. 2018;23:56-61. [Pubmed]